DPP4 and obesity disorder: GLP-1 promotes glucose-dependent insulin secretion and satiety, and has been translated into therapies for type 2 diabetes and obesity through the development of long acting GLP-1 mimetics and inhibitors of dipeptidyl peptidase 4 (DPP4) [2].